Scope
This NICE clinical guideline (CG141) covers the management of acute upper gastrointestinal bleeding in people over 16. It addresses: - formal risk scoring before and after endoscopy; - resuscitation, including transfusion and blood-product thresholds; - anticoagulant reversal, including warfarin and DOACs; - timing and service organisation of endoscopy; - endoscopic, pharmacological, radiological and surgical management of non-variceal and variceal bleeding; - handling of aspirin, other NSAIDs and clopidogrel; - acid-suppression prophylaxis in critically ill patients; - communication with patients and carers. NICE's wording ('offer', 'consider', 'do not') conveys recommendation strength. This summary preserves those distinctions.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Risk assessment
Resuscitation, transfusion and anticoagulant reversal
- In massive bleeding, give blood, platelets and clotting factors according to local protocols for managing massive bleeding. Base blood transfusion decisions on the full clinical picture. Over-transfusion may be as damaging as under-transfusion. [1]
- Platelet transfusion: - Do not give platelets to haemodynamically stable patients who are not actively bleeding. - Offer platelets to actively bleeding patients with a platelet count below 50 x 10^9/litre. [1]
- Fresh frozen plasma and cryoprecipitate: - Offer fresh frozen plasma to actively bleeding patients whose PT (or INR) or APTT is more than 1.5 times normal. - Add cryoprecipitate if fibrinogen stays below 1.5 g/litre despite fresh frozen plasma. [1]
- Patients on warfarin: - If actively bleeding, offer prothrombin complex concentrate. - If the bleeding has stopped, manage according to local warfarin protocols. Use recombinant factor VIIa only when all other methods have failed. [1]
- DOAC reversal: - For reversal agents, the guideline refers to MHRA safety advice. - The guideline cites NICE technology appraisal guidance recommending andexanet alfa as an option for reversing apixaban or rivaroxaban in adults with life-threatening or uncontrolled GI bleeding. [1]
Timing of endoscopy
- Endoscopy timing: - Offer endoscopy to unstable patients with severe bleeding immediately after resuscitation. - Offer endoscopy to all other patients within 24 hours of admission. [1]
- Service organisation: - Units managing more than 330 cases annually should provide daily endoscopy lists. - Units managing fewer than 330 cases should organise services to suit local circumstances. [1]
Non-variceal bleeding
- Do not use adrenaline alone for endoscopic treatment of non-variceal bleeding. Use one of the following: - a mechanical method such as clips, with or without adrenaline; - thermal coagulation combined with adrenaline; - fibrin or thrombin combined with adrenaline. [1]
- Acid suppression: - Do not give PPIs or H2-receptor antagonists before endoscopy when non-variceal bleeding is suspected. - Offer PPIs when endoscopy shows stigmata of recent haemorrhage. [1]
- Repeat endoscopy: - Consider repeat endoscopy, with treatment as needed, for patients at high re-bleeding risk, especially if haemostasis at the first procedure was doubtful. - Offer repeat endoscopy to patients who re-bleed, with a view to further endoscopic treatment or emergency surgery. [1]
- Offer interventional radiology to unstable patients who re-bleed after endoscopic treatment. If interventional radiology is not promptly available, refer urgently for surgery. [1]
Variceal bleeding
- Offer terlipressin at presentation when variceal bleeding is suspected. - Stop it once definitive haemostasis is achieved, or after 5 days, unless there is another indication. - Licensing note: at publication (June 2012), terlipressin was indicated for bleeding from oesophageal varices, with a maximum treatment duration of 72 hours (3 days). - Prescribers should consult the relevant summary of product characteristics. - Obtain and document informed consent for off-label use. [1]
- Offer prophylactic antibiotics at presentation for suspected or confirmed variceal bleeding. [1]
- For bleeding oesophageal varices, use band ligation. Consider TIPS if band ligation does not control the bleeding. [1]
- For bleeding gastric varices, offer endoscopic injection of N-butyl-2-cyanoacrylate. Offer TIPS if this does not control the bleeding. [1]
Patients on NSAIDs, aspirin or clopidogrel
- Aspirin and other NSAIDs: - Once haemostasis is achieved, continue low-dose aspirin given for secondary prevention of vascular events. - Stop other NSAIDs, including COX-2 inhibitors, during the acute phase. [1]
- Discuss the risks and benefits of continuing clopidogrel or another thienopyridine with the patient and with the relevant specialist, such as a cardiologist or stroke specialist. [1]
Critical care prophylaxis and patient communication
- Offer acid suppression to acutely ill patients admitted to critical care to prevent upper GI bleeding. Either an H2-receptor antagonist or a PPI may be used, preferably in oral form. - Licensing note: the source states that, as of September 2023, using any PPI or H2-receptor antagonist other than ranitidine and cimetidine for this indication would be off label. It adds that ranitidine is currently unavailable and refers readers to the MHRA drug alert on ranitidine. - Review: reassess the ongoing need when the patient recovers or is discharged from critical care. [1]
- Maintain good communication with patients, family and carers from presentation, throughout the hospital stay and after discharge. This includes: - recording verbal information in the medical records; - ensuring consistent information from all team members; - giving written information where appropriate. [1]
Limitations and use
- Applies to people over 16 with acute upper gastrointestinal bleeding; younger patients are outside scope.
- Only the recommendation pages were summarised; research recommendations and supporting rationale or evidence sections were not reviewed.
- The reviewed text includes notes dated September 2023 and a reference to a 2025 technology appraisal, so it reflects updates later than the original publication. The terlipressin licensing and acid-suppressant notes are time-specific; check current product information.
- DOAC reversal is covered only by cross-reference to MHRA advice and NICE TA guidance on andexanet alfa; those documents were not reviewed.
- Several recommendations defer to local protocols (massive bleeding, warfarin management) whose content the source does not specify.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Acute upper gastrointestinal bleeding in over 16s: management
Guideline recommendation text consulted
Publication details
- Issuing organisation
- NICE
- First published
- 13 June 2012
- Publisher’s latest update
- 25 August 2016
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.